Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.
Onishi M, Graf SA, Holmberg L, Behnia S, Shustov AR, Schiavo K, Philip M, Libby EN, Cassaday RD, Pagel JM, Roden JE, Maloney DG, Green DJ, Till BG, Press OW, Smith SD, Gopal AK.
Onishi M, et al. Among authors: roden je.
Hematol Oncol. 2015 Dec;33(4):187-91. doi: 10.1002/hon.2166. Epub 2014 Sep 18.
Hematol Oncol. 2015.
PMID: 25236531
Free PMC article.